Close Menu

Almac

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Almac today said that it is teaming up with researchers at Queen's University, Belfast to develop pharmacogenomics tests for a variety of cancers.

Almac will run AclarusDx on the Affymetrix Dx2 platform. The test is based on Exonhit's proprietary biochip, a customized Affy GeneChip called the Genome Wide SpliceArray.

Paris-based Exonhit has already introduced AclarusDx to the French market and is planning to launch it in the wider European market.

Almac will analyze all samples performed with Exonhit's blood-based AclarusDx test.

Affymetrix, Almac Diagnostics, and Oxford Gene Technology are among the firms that have been awarded funding to develop new approaches for tumor profiling and data capture.

Almac researchers and academic collaborators used the company's Disease Specific Array platform to identify biomarkers associated with ovarian and breast cancer.

Almac, headquartered in Craigavon, Northern Ireland, said the new CLIA-registered lab supports its biomarker discovery and development strategy by "enabling the use of novel tests to stratify and enrich prospective clinical trials."

The firm said the lab will support its own needs as well as those of its pharmaceutical partners.

BioFocus has launched an FLT screening and profiling service using Almac's Flexyte assay platform and is offering services against targets such as proteases, phosphatases, and kinases.

Skyline Diagnostics' AMLprofiler leukemia test recently became the fourth Affy-based test to hit the market. Some of the company's other diagnostic partners, however, have changed their development strategies since the "Powered by Affymetrix" program was launched.

Pages

A new analysis finds that nearly half the late-stage clinical trials sponsored by a US National Cancer Institute program influence patient care.

Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.

The owner of the GEDmatch website tells CBS12 he is considering charging law enforcement a fee to use the site.

In Nature this week: babies born by caesarean section are more likely to have altered gut microbiota profiles, and more.